Xiulan Yang1, Marita Rodriguez2, Lil Pabon1, Karin A Fischer3, Hans Reinecke1, Michael Regnier4, Nathan J Sniadecki5, Hannele Ruohola-Baker3, Charles E Murry6. 1. Department of Pathology, University of Washington, Seattle, WA 98109, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. 2. Department of Mechanical Engineering, University of Washington, Seattle, WA 98109, USA. 3. Department of Biochemistry, University of Washington, Seattle, WA 98109, USA. 4. Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. 5. Department of Mechanical Engineering, University of Washington, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98109, USA. 6. Department of Pathology, University of Washington, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Department of Medicine/Cardiology, University of Washington, Seattle, WA 98109, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. Electronic address: murry@uw.edu.
Abstract
BACKGROUND: Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) have great potential as a cell source for therapeutic applications such as regenerative medicine, disease modeling, drug screening, and toxicity testing. This potential is limited, however, by the immature state of the cardiomyocytes acquired using current protocols. Tri-iodo-l-thyronine (T3) is a growth hormone that is essential for optimal heart growth. In this study, we investigated the effect of T3 on hiPSC-CM maturation. METHODS AND RESULTS: A one-week treatment with T3 increased cardiomyocyte size, anisotropy, and sarcomere length. T3 treatment was associated with reduced cell cycle activity, manifest as reduced DNA synthesis and increased expression of the cyclin-dependent kinase inhibitor p21. Contractile force analyses were performed on individual cardiomyocytes using arrays of microposts, revealing an almost two-fold higher force per-beat after T3 treatment and also an enhancement in contractile kinetics. This improvement in force generation was accompanied by an increase in rates of calcium release and reuptake, along with a significant increase in sarcoendoplasmic reticulum ATPase expression. Finally, although mitochondrial genomes were not numerically increased, extracellular flux analysis showed a significant increase in maximal mitochondrial respiratory capacity and respiratory reserve capability after T3 treatment. CONCLUSIONS: Using a broad spectrum of morphological, molecular, and functional parameters, we conclude that T3 is a driver for hiPSC-CM maturation. T3 treatment may enhance the utility of hiPSC-CMs for therapy, disease modeling, or drug/toxicity screens.
BACKGROUND: Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) have great potential as a cell source for therapeutic applications such as regenerative medicine, disease modeling, drug screening, and toxicity testing. This potential is limited, however, by the immature state of the cardiomyocytes acquired using current protocols. Tri-iodo-l-thyronine (T3) is a growth hormone that is essential for optimal heart growth. In this study, we investigated the effect of T3 on hiPSC-CM maturation. METHODS AND RESULTS: A one-week treatment with T3 increased cardiomyocyte size, anisotropy, and sarcomere length. T3 treatment was associated with reduced cell cycle activity, manifest as reduced DNA synthesis and increased expression of the cyclin-dependent kinase inhibitor p21. Contractile force analyses were performed on individual cardiomyocytes using arrays of microposts, revealing an almost two-fold higher force per-beat after T3 treatment and also an enhancement in contractile kinetics. This improvement in force generation was accompanied by an increase in rates of calcium release and reuptake, along with a significant increase in sarcoendoplasmic reticulum ATPase expression. Finally, although mitochondrial genomes were not numerically increased, extracellular flux analysis showed a significant increase in maximal mitochondrial respiratory capacity and respiratory reserve capability after T3 treatment. CONCLUSIONS: Using a broad spectrum of morphological, molecular, and functional parameters, we conclude that T3 is a driver for hiPSC-CM maturation. T3 treatment may enhance the utility of hiPSC-CMs for therapy, disease modeling, or drug/toxicity screens.
Authors: John L Tan; Joe Tien; Dana M Pirone; Darren S Gray; Kiran Bhadriraju; Christopher S Chen Journal: Proc Natl Acad Sci U S A Date: 2003-01-27 Impact factor: 11.205
Authors: Ning Sun; Masayuki Yazawa; Jianwei Liu; Leng Han; Veronica Sanchez-Freire; Oscar J Abilez; Enrique G Navarrete; Shijun Hu; Li Wang; Andrew Lee; Aleksandra Pavlovic; Shin Lin; Rui Chen; Roger J Hajjar; Michael P Snyder; Ricardo E Dolmetsch; Manish J Butte; Euan A Ashley; Michael T Longaker; Robert C Robbins; Joseph C Wu Journal: Sci Transl Med Date: 2012-04-18 Impact factor: 17.956
Authors: Rebecca E Taylor; Keekyoung Kim; Ning Sun; Sung-Jin Park; Joo Yong Sim; Giovanni Fajardo; Daniel Bernstein; Joseph C Wu; Beth L Pruitt Journal: Biomed Microdevices Date: 2013-02 Impact factor: 2.838
Authors: Ashley H Fong; Mónica Romero-López; Christopher M Heylman; Mark Keating; David Tran; Agua Sobrino; Anh Q Tran; Hiep H Pham; Cristhian Fimbres; Paul D Gershon; Elliot L Botvinick; Steven C George; Christopher C W Hughes Journal: Tissue Eng Part A Date: 2016-08 Impact factor: 3.845
Authors: Oscar J Abilez; Evangeline Tzatzalos; Huaxiao Yang; Ming-Tao Zhao; Gwanghyun Jung; Alexander M Zöllner; Malte Tiburcy; Johannes Riegler; Elena Matsa; Praveen Shukla; Yan Zhuge; Tony Chour; Vincent C Chen; Paul W Burridge; Ioannis Karakikes; Ellen Kuhl; Daniel Bernstein; Larry A Couture; Joseph D Gold; Wolfram H Zimmermann; Joseph C Wu Journal: Stem Cells Date: 2017-11-13 Impact factor: 6.277